<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01175369</url>
  </required_header>
  <id_info>
    <org_study_id>12308</org_study_id>
    <secondary_id>1R01HL079954-01A1</secondary_id>
    <nct_id>NCT01175369</nct_id>
    <nct_alias>NCT00296998</nct_alias>
  </id_info>
  <brief_title>School-based Asthma Therapy: Stage 2 Effectiveness Study</brief_title>
  <acronym>SBAT</acronym>
  <official_title>School-Based Asthma Therapy: Stage 2 Effectiveness Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Halcyon Hill Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asthma is the most common chronic illness of childhood, and hospitalization rates are
      increasing. In the US, impoverished children and children from minority ethnic and racial
      backgrounds suffer disproportionately from asthma. While National Heart, Lung, and Blood
      Institute (NHLBI) guidelines recommend daily preventive medications for all children with
      mild persistent to severe persistent asthma, studies indicate that many children in the US
      who should receive preventive medications are not receiving them. The overall goal of this
      project is to target an ethnically diverse population of inner-city schoolchildren with
      asthma and explore a school-based program to reduce asthma morbidity. We hypothesize that
      children receiving a comprehensive school-based intervention will experience less
      asthma-related morbidity compared to children receiving usual care. Our comprehensive
      school-based intervention consists of both administration of recommended preventive asthma
      medications in school (with dose adjustments according to NHLBI guidelines) and an
      environmental tobacco smoke (ETS) reduction program in the home for smoke-exposed children.
      Our secondary hypothesis is that, among the subgroup of smoke-exposed children, those who
      receive the school-based intervention with ETS reduction will experience less asthma
      morbidity than those who receive usual care.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Symptom Free Days</measure>
    <time_frame>Average Symptom Free Days, over 2 weeks, during peak asthma season (November-February)</time_frame>
    <description>The primary outcome variable is the average number of symptom free days over 2 weeks assessed during peak asthma season (data collected during November, December, January and February during the school year).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cotinine Level</measure>
    <time_frame>2 month and approximately 9 month (end of school year) follow-up assessments</time_frame>
    <description>To test the effectiveness of the environmental tobacco smoke (ETS) reduction portion of the study, we will compare baseline cotinine values to 2 month (for smoke exposed participants) and final follow-up assessments (for all participants).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost Effectiveness of the Intervention</measure>
    <time_frame>approximately 9 months (length of school year)</time_frame>
    <description>Cost-effectiveness will examine the net program costs to the number of symptom-free days gained. Benefits will be described as the net difference in medical and productivity costs between children in the treatment and control groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional Asthma Morbidity Outcomes</measure>
    <time_frame>1-9 months (Monthly Follow-up assessments)</time_frame>
    <description>We will look at additional asthma morbidity outcomes including symptom nights, days needing rescue medications, functional severity, days absent from school, and quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">530</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual asthma care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>School-based Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>School-based Care</intervention_name>
    <description>The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).</description>
    <arm_group_label>School-based Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physician-diagnosed asthma

          -  Mild persistent to severe persistent asthma

          -  Ages 3-10 years

          -  Attending school in the Rochester City School District preschools or elementary
             schools

          -  Signed physician permission to enroll the child

          -  Parent or caregiver must consent to the intervention

        Exclusion Criteria:

          -  Inability to speak and understand either English or Spanish

          -  No access to a working phone for follow-up surveys

          -  The family planning to leave the school district within fewer than 6 months

          -  The child having other significant medical conditions that could interfere with the
             assessment of asthma-related outcome measures

          -  children in foster care or other situations in which consent cannot be obtained from a
             guardian

          -  Current participation in other local asthma interventions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jill S. Halterman, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Halterman JS, Borrelli B, Fisher S, Szilagyi P, Yoos L. Improving care for urban children with asthma: design and methods of the School-Based Asthma Therapy (SBAT) trial. J Asthma. 2008 May;45(4):279-86. doi: 10.1080/02770900701854908.</citation>
    <PMID>18446591</PMID>
  </reference>
  <reference>
    <citation>Fagnano M, van Wijngaarden E, Connolly HV, Carno MA, Forbes-Jones E, Halterman JS. Sleep-disordered breathing and behaviors of inner-city children with asthma. Pediatrics. 2009 Jul;124(1):218-25. doi: 10.1542/peds.2008-2525.</citation>
    <PMID>19564303</PMID>
  </reference>
  <reference>
    <citation>Conn KM, Hernandez T, Puthoor P, Fagnano M, Halterman JS. Screen time use among urban children with asthma. Acad Pediatr. 2009 Jan-Feb;9(1):60-3. doi: 10.1016/j.acap.2008.10.001.</citation>
    <PMID>19329093</PMID>
  </reference>
  <reference>
    <citation>Halterman JS, Borrelli B, Tremblay P, Conn KM, Fagnano M, Montes G, Hernandez T. Screening for environmental tobacco smoke exposure among inner-city children with asthma. Pediatrics. 2008 Dec;122(6):1277-83. doi: 10.1542/peds.2008-0104.</citation>
    <PMID>19047246</PMID>
  </reference>
  <reference>
    <citation>Halterman JS, Borrelli B, Conn KM, Tremblay P, Blaakman S. Motivation to quit smoking among parents of urban children with asthma. Patient Educ Couns. 2010 May;79(2):152-5. doi: 10.1016/j.pec.2009.09.004. Epub 2009 Sep 30.</citation>
    <PMID>19796913</PMID>
  </reference>
  <reference>
    <citation>Shone LP, Conn KM, Sanders L, Halterman JS. The role of parent health literacy among urban children with persistent asthma. Patient Educ Couns. 2009 Jun;75(3):368-75. doi: 10.1016/j.pec.2009.01.004. Epub 2009 Feb 23.</citation>
    <PMID>19233588</PMID>
  </reference>
  <reference>
    <citation>Fagnano M, Conn KM, Halterman JS. Environmental tobacco smoke and behaviors of inner-city children with asthma. Ambul Pediatr. 2008 Sep-Oct;8(5):288-93. doi: 10.1016/j.ambp.2008.04.002. Epub 2008 May 12.</citation>
    <PMID>18922501</PMID>
  </reference>
  <reference>
    <citation>Fagnano M, Bayer AL, Isensee CA, Hernandez T, Halterman JS. Nocturnal asthma symptoms and poor sleep quality among urban school children with asthma. Acad Pediatr. 2011 Nov-Dec;11(6):493-9. doi: 10.1016/j.acap.2011.05.006. Epub 2011 Aug 3.</citation>
    <PMID>21816697</PMID>
  </reference>
  <reference>
    <citation>Fagnano M, Halterman JS, Conn KM, Shone LP. Health literacy and sources of health information for caregivers of urban children with asthma. Clin Pediatr (Phila). 2012 Mar;51(3):267-73. doi: 10.1177/0009922811421413. Epub 2011 Sep 12.</citation>
    <PMID>21911409</PMID>
  </reference>
  <reference>
    <citation>Blaakman S, Tremblay PJ, Halterman JS, Fagnano M, Borrelli B. Implementation of a community-based secondhand smoke reduction intervention for caregivers of urban children with asthma: process evaluation, successes and challenges. Health Educ Res. 2013 Feb;28(1):141-52. doi: 10.1093/her/cys070. Epub 2012 Jun 20.</citation>
    <PMID>22717938</PMID>
  </reference>
  <reference>
    <citation>Noyes K, Bajorska A, Fisher S, Sauer J, Fagnano M, Halterman JS. Cost-effectiveness of the School-Based Asthma Therapy (SBAT) program. Pediatrics. 2013 Mar;131(3):e709-17. doi: 10.1542/peds.2012-1883. Epub 2013 Feb 11.</citation>
    <PMID>23400614</PMID>
  </reference>
  <reference>
    <citation>Koehler AD, Fagnano M, Montes G, Halterman JS. Elevated burden for caregivers of children with persistent asthma and a developmental disability. Matern Child Health J. 2014 Nov;18(9):2080-8. doi: 10.1007/s10995-014-1455-6.</citation>
    <PMID>24619226</PMID>
  </reference>
  <reference>
    <citation>Evans KA, Halterman JS, Hopke PK, Fagnano M, Rich DQ. Increased ultrafine particles and carbon monoxide concentrations are associated with asthma exacerbation among urban children. Environ Res. 2014 Feb;129:11-9. doi: 10.1016/j.envres.2013.12.001. Epub 2014 Jan 11.</citation>
    <PMID>24528997</PMID>
  </reference>
  <results_reference>
    <citation>Halterman JS, Szilagyi PG, Fisher SG, Fagnano M, Tremblay P, Conn KM, Wang H, Borrelli B. Randomized controlled trial to improve care for urban children with asthma: results of the School-Based Asthma Therapy trial. Arch Pediatr Adolesc Med. 2011 Mar;165(3):262-8. doi: 10.1001/archpediatrics.2011.1.</citation>
    <PMID>21383275</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2010</study_first_submitted>
  <study_first_submitted_qc>August 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2010</study_first_posted>
  <results_first_submitted>January 14, 2013</results_first_submitted>
  <results_first_submitted_qc>January 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 15, 2013</results_first_posted>
  <last_update_submitted>July 25, 2014</last_update_submitted>
  <last_update_submitted_qc>July 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Jill Halterman</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Usual Care</title>
          <description>Usual asthma care</description>
        </group>
        <group group_id="P2">
          <title>School-based Care</title>
          <description>The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="265"/>
                <participants group_id="P2" count="265"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="263"/>
                <participants group_id="P2" count="260"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Usual Care</title>
          <description>Usual asthma care</description>
        </group>
        <group group_id="B2">
          <title>School-based Care</title>
          <description>The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="265"/>
            <count group_id="B2" value="265"/>
            <count group_id="B3" value="530"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="265"/>
                    <measurement group_id="B2" value="265"/>
                    <measurement group_id="B3" value="530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.2" spread="1.9"/>
                    <measurement group_id="B2" value="7.1" spread="2.0"/>
                    <measurement group_id="B3" value="7.1" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="265"/>
                    <measurement group_id="B2" value="265"/>
                    <measurement group_id="B3" value="530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Symptom Free Days</title>
        <description>The primary outcome variable is the average number of symptom free days over 2 weeks assessed during peak asthma season (data collected during November, December, January and February during the school year).</description>
        <time_frame>Average Symptom Free Days, over 2 weeks, during peak asthma season (November-February)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Usual asthma care</description>
          </group>
          <group group_id="O2">
            <title>School-based Care</title>
            <description>The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Symptom Free Days</title>
          <description>The primary outcome variable is the average number of symptom free days over 2 weeks assessed during peak asthma season (data collected during November, December, January and February during the school year).</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="3.1"/>
                    <measurement group_id="O2" value="11.6" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cotinine Level</title>
        <description>To test the effectiveness of the environmental tobacco smoke (ETS) reduction portion of the study, we will compare baseline cotinine values to 2 month (for smoke exposed participants) and final follow-up assessments (for all participants).</description>
        <time_frame>2 month and approximately 9 month (end of school year) follow-up assessments</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cost Effectiveness of the Intervention</title>
        <description>Cost-effectiveness will examine the net program costs to the number of symptom-free days gained. Benefits will be described as the net difference in medical and productivity costs between children in the treatment and control groups.</description>
        <time_frame>approximately 9 months (length of school year)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Additional Asthma Morbidity Outcomes</title>
        <description>We will look at additional asthma morbidity outcomes including symptom nights, days needing rescue medications, functional severity, days absent from school, and quality of life.</description>
        <time_frame>1-9 months (Monthly Follow-up assessments)</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Usual Care</title>
          <description>Usual asthma care</description>
        </group>
        <group group_id="E2">
          <title>School-based Care</title>
          <description>The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="265"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jill Halterman</name_or_title>
      <organization>University of Rochester</organization>
      <phone>5852755798</phone>
      <email>jill_halterman@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

